Phase i study combining PARP-inhibition with immune checkpoint blockade in women with BRCA-deficient recurrent ovarian cancer

Authors
Category Primary study
JournalGynecologic Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 41fdf878077edd918950ce87f3c27ce52415b2d6
First added on: Feb 08, 2025